TTrialPathMatch Me to Trials
← Back to trials
RecruitingAcute Lymphocytic Leukemia (ALL)

Phase 2 Study Assessing the Clinical Activity and Safety of Obecabtagene Autoleucel as a Consolidation in Patients With Newly Diagnosed High-risk B-cell Acute Lymphocytic Leukemia (ALL)

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The goal of this clinical research study is to learn if obecabtagene autoleucel (obe-cel) can help to control newly diagnosed, high-risk B-cell ALL when given as consolidation therapy. Consolidation therapy is given after the first phase of treatment.

Sponsor: M.D. Anderson Cancer Center

You may qualify if…

  • ✓ I. Patients of age .18 years with high-risk B-cell ALL in first remission and \<5% BM blasts with at least one high-risk feature defined as:
  • ✓ 1. Ph-negative B-cell ALL:
  • ✓ 1. KMT2A rearranged ALL
  • ✓ 2. Complex cytogenetics as per NCCN 2022
  • ✓ 3. Low-hypodiploidy/tetraploidy
  • ✓ 4. Philadelphia-like ALL (based on CRLF2 overexpression or recurrent Ph-like genetic fusions)
  • ✓ 5. TP53 mutation (variant allele fraction \>2%)
  • ✓ 6. Persistent MRD by flow cytometry and/or NGS

You may not qualify if…

  • ✕ 1. Pregnant or lactating; women of child-bearing potential (WOCBP) must have negative pregnancy test. WOCBP defined as not post-menopausal for 12 months or no previous surgical sterilization.
  • ✕ 2. Patients with history of Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV) infections, even if under control. (Patients with Hepatitis B core antibody positive alone will not be an exclusion factor if HBV DNA PCR is negative).
  • ✕ 3. Active and uncontrolled disease/infection as judged by the treating physician
  • ✕ 4. Unable or unwilling to sign the consent form

Where it's recruiting

Texas

Houston

Source: ClinicalTrials.gov · NCT07053059 · last updated 2026-08-12